Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: Role of delayed-release fenofibric acid

Susan M. Schima, Stephanie R. MacIejewski, Daniel E. Hilleman, Mark A. Williams, Syed M. Mohiuddin

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Importance of the field: Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust. Areas covered in this review: The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed. What the reader will gain: The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin. Take home message: Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.

Original languageEnglish
Pages (from-to)731-738
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number5
DOIs
StatePublished - Apr 2010

Fingerprint

Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Lipids
LDL Cholesterol
Cholesterol
Rhabdomyolysis
Muscular Diseases
Therapeutics
Carbon Monoxide
MEDLINE
Pharmaceutical Preparations
HDL Cholesterol
Oxidoreductases
Cardiovascular Diseases
Safety
fenofibric acid

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology

Cite this

Fibrate therapy in the management of dyslipidemias, alone and in combination with statins : Role of delayed-release fenofibric acid. / Schima, Susan M.; MacIejewski, Stephanie R.; Hilleman, Daniel E.; Williams, Mark A.; Mohiuddin, Syed M.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 5, 04.2010, p. 731-738.

Research output: Contribution to journalReview article

@article{101b41b3aec24f8794c56bc4f67982ab,
title = "Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: Role of delayed-release fenofibric acid",
abstract = "Importance of the field: Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust. Areas covered in this review: The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed. What the reader will gain: The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin. Take home message: Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.",
author = "Schima, {Susan M.} and MacIejewski, {Stephanie R.} and Hilleman, {Daniel E.} and Williams, {Mark A.} and Mohiuddin, {Syed M.}",
year = "2010",
month = "4",
doi = "10.1517/14656560903575639",
language = "English",
volume = "11",
pages = "731--738",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Fibrate therapy in the management of dyslipidemias, alone and in combination with statins

T2 - Role of delayed-release fenofibric acid

AU - Schima, Susan M.

AU - MacIejewski, Stephanie R.

AU - Hilleman, Daniel E.

AU - Williams, Mark A.

AU - Mohiuddin, Syed M.

PY - 2010/4

Y1 - 2010/4

N2 - Importance of the field: Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust. Areas covered in this review: The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed. What the reader will gain: The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin. Take home message: Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.

AB - Importance of the field: Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust. Areas covered in this review: The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed. What the reader will gain: The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin. Take home message: Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.

UR - http://www.scopus.com/inward/record.url?scp=77949447243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949447243&partnerID=8YFLogxK

U2 - 10.1517/14656560903575639

DO - 10.1517/14656560903575639

M3 - Review article

C2 - 20210682

AN - SCOPUS:77949447243

VL - 11

SP - 731

EP - 738

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -